Updated for our 20th year, the 'MMV At a glance' highlights our unique partnership model, the increasing impact of our access work and the portfolio of medicines that has grown and evolved since 1999.
As our 20th anniversary nears, two MMV drug discovery scientists, Dr Didier Leroy and Dr Brice Campo, discuss advancements that have been made and the challenges that lie ahead in the discovery of antimalarial medicines.
This month, in celebration of International Women’s Day, MMV women in R&D discuss childhood heroines, progress that has been made for women in science over the course of their careers and inspiring young women to follow a science path.
This film illustrates how MMV works with a broad network of partners cultivated since 1999. Together with over 150 scientists, researchers, healthcare workers, policy makers and others, we work to design, test, create and deliver new medicines for the treatment and prevention of malaria.
Since 1999, MMV and its public and private partners have brought forward 12 new medicines which have saved the lives of 1.9 million people. This image slideshow depicts their stories.
Global efforts to tackle malaria have historically focused on Plasmodium falciparum. To achieve the malaria elimination goal, however, efforts will need to also focus on reducing the burden of relapsing P. vivax malaria. In this interview, Dr Kamini Mendis, Independent Consultant in Malaria and Tropical Medicine, discusses the successes in eliminating malaria in Southeast Asia, and the challenges that lie ahead.
Over the past 20 years, artemisinin-based medicines have contributed to a significant decrease in malaria-related mortality. Over the next 20, resistance to existing medicines will be one of the toughest challenges we face. This image slideshow outlines how MMV’s portfolio is geared up to tackle antimalarial drug resistance.
In 1999, MMV and partners set out to discover, develop and deliver medicines to treat and prevent malaria in endemic countries. As our 20th anniversary nears, we reflect on the lives our collaborative innovation has touched. Tenin’s is one of them. Read her story.
From “enthusiastic amateur” to indispensable contributor: 20 years of service to malaria drug discovery
Since the day he answered MMV’s ad in Nature for drug discovery expertise, Sir Simon Campbell has been a stalwart supporter and indispensable contributor to MMV’s work. Not only was he part of the group that helped to establish MMV, he has provided mentorship to a number of the project teams that have delivered MMV's clinical candidates. Sir Simon tells us about what it was like to take part in MMV’s beginnings and how he sees the organization developing over the next decades.
Along the road to health impact in the fight against malaria MMV encounters new people, places and ideas. Over the past 20 years these experiences have shaped the way we work to design, create and ultimately deliver new medicines to vulnerable populations. Here are four staff interviews on some of their most memorable encounters.
In celebration of MMV's 20th anniversary this month, Board members reflect on past successes, challenges and future aspirations for the role of MMV within the evolving malaria landscape.